Merck & Company Inc (MRK)vsQiagen NV (QGEN)
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
QGEN
Qiagen NV
$36.68
-2.34%
HEALTHCARE · Cap: $7.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 3034% more annual revenue ($65.77B vs $2.10B). QGEN leads profitability with a 19.2% profit margin vs 13.6%. QGEN appears more attractively valued with a PEG of 0.93. QGEN earns a higher WallStSmart Score of 61/100 (C+).
MRK
Hold50
out of 100
Grade: D+
QGEN
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Margin of Safety
-26.4%
Fair Value
$40.38
Current Price
$36.68
$3.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 23.8%
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
1.8% revenue growth
Earnings declined 23.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : QGEN
The strongest argument for QGEN centers on PEG Ratio, Price/Book, Operating Margin. Profitability is solid with margins at 19.2% and operating margin at 23.8%. PEG of 0.93 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : QGEN
The primary concerns for QGEN are Revenue Growth, EPS Growth.
Key Dynamics to Monitor
QGEN carries more volatility with a beta of 0.66 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
QGEN scores higher overall (61/100 vs 50/100), backed by strong 19.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Qiagen NV
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?